Drugs / SAR447537
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05897424 | Jun 2024 → Jun 2028 expected | alpha 1-antitrypsin deficiency, pulmonary emphysema | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05856331 | Oct 2023 → Aug 2025 | alpha 1-antitrypsin deficiency, pulmonary emphysema | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR447537 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05897424 ↗ |
| Known as | INBRX-101 | “Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema” NCT05897424 ↗1“Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema” NCT05856331 ↗ |
| Modality | Protein / enzyme biologic | “A1PI, Recombinant, Bivalent Fc Fusion Protein” NCT05856331 ↗ |
| Route | Intravenous | “IV every 3-weeks (Q3W) and placebo (normal saline)” NCT05856331 ↗ |